• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·7733.T
Share

Olympus Corporation Stocks

¥ 1751Last Updated 27.10.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

¥ 11.66B

¥ 1751
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

29.08.2025 11:42

Goldman and Morgan Stanley differed in their forecasts for Chinese stocks. Is the market already overheated?

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. Its reach extends across Japan, the Americas, the Middle East, Asia, and Oceania. The company structures its operations around three primary divisions: Endoscopic Solutions, Therapeutic Solutions, and Other business segments. Its extensive product portfolio includes advanced gastrointestinal endoscopy systems, incorporating video and ultrasound technologies, as well as GI endotherapy tools for treating colorectal conditions, HPB (hepatopancreatobiliary) issues, and hemostasis. Olympus also delivers comprehensive endoscopic ecosystem solutions, which feature intelligent operating software platforms, AI-driven insights, and computer-aided detection and diagnosis functionalities. Furthermore, it provides reprocessing solutions for endoscopes, including reprocessors, chemicals, and related accessories, supported by essential medical services such as repair center operations. The company also supplies respiratory care devices, offering bronchoscopy systems and solutions for lung cancer and chronic obstructive pulmonary disease. Its urology offerings encompass visualization tools, stone management, and treatments for benign prostatic hyperplasia (BPH) and BPH with bladder cancer. Within its surgical segment, Olympus features surgical endoscopy systems, cutting-edge energy devices, surgical microscopes, integrated operating room solutions, rhino-laryngoscopy systems, and instruments tailored for ear, nose, and throat surgeries. Various gastroenterology and gynecology devices further round out its product offerings. Established in 1919, the company was initially known as Olympus Optical Co., Ltd., before officially changing its name to Olympus Corporation in October 2003. Its global headquarters are situated in Hachioji, Japan.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 7733.T is 2032 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 09:01

Insiders, a competitor, a philanthropist, and an activist: Who owns shares in Anthropic?

28.10.2026 08:30

Wall Street has identified Broadcom as a major beneficiary of Anthropic's IPO. Who else stands to gain?

28.10.2026 08:01

"Too Big a Chicken": McDonald's Partners Deem the New Menu a Failure

28.10.2026 07:01

Healthcare stocks have become a bet against AI. Should you buy them?

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026